

## II. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended) A method for treating posterior segment neovascularization which comprises, administering a pharmaceutically effective amount of a selective PDE-IV inhibitor, wherein the selective PDE-IV inhibitor is selected from the group consisting of 2-(4-ethoxycarbonylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydro-pyridazin-3-one, 3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(ethylamino)-8-isopropyl-3H-purine hydrochloride (V-11294A), 8-methoxyquinoline-5-[N-(2,5-dichloropyridin-3-yl)]carboxamide (D-4418), cipamylline (BRL 61063), ariflo (SB-207499), and derivatives thereof.

Claim 2 (previously presented) The method of claim 1, wherein the posterior segment neovascularization is age-related macular degeneration.

Claim 3 (previously presented) The method of claim 2, wherein the age-related macular degeneration is exudative age-related macular degeneration.

Claim 4 (previously presented) The method of claim 1, wherein the posterior segment neovascularization is diabetic retinopathy.

Claim 5 (previously presented) The method of claim 4, wherein the diabetic retinopathy is proliferative diabetic retinopathy.

Claim 6 (previously presented) The method of claim 1, wherein the selective PDE-IV inhibitor is administered by oral administration, transdermally, subdermally, intraperitoneally, subcutaneously, transnasally, sublingually, rectally, by topical ocular administration, intravitreally, periocularly, transclerally, retrobulbar administration, sub-tenon injection, or via an intraocular device.